Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02933736 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | active not recruiting | Early Phase 1 | 48 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases | recruiting | Early Phase 1 | 15 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | not yet recruiting | Phase 1 | 40 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05925218 | Circulating Tumor DNA Collection From Patients With High Grade Gliomas(m-ctDNA) | active not recruiting | — | 70 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06917885 | CUE-102 in Recurrent Glioblastoma | recruiting | Phase 1 | 18 | David Reardon, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04908709 | Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors | recruiting | N/A | 25 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06546631 | Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients(Improve TMZ) | recruiting | — | 55 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07448480 | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas(GLIOTARG) | active not recruiting | — | 1,000 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04243005 | Supramarginal Resection in Glioblastoma | active not recruiting | N/A | 90 | St. Olavs HospitalOTHER | 6 | Mar 3, 2026 | clinicaltrials |
| NCT07447531 | T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas | recruiting | N/A | 15 | John M. BuattiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04425434 | Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma(GFARB12019) | recruiting | — | 3,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT06719440 | Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume(BELGICA) | recruiting | N/A | 347 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07438860 | Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG | not yet recruiting | Phase 1 | 12 | Tiffany HodgesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.(PRC) | not yet recruiting | Phase 2 | 70 | The Cooper Health SystemOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07439302 | Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma(NEURO-PRO-GLIO) | not yet recruiting | N/A | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02125786 | A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | active not recruiting | Phase 2 | 68 | St. Jude Children's Research HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07236840 | Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors(NEMO) | recruiting | — | 600 | Tata Memorial CentreOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07405372 | Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas | recruiting | — | 10 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06058988 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426848 | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients(OTSMILE) | recruiting | N/A | 96 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417774 | Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic(RESTORE LB) | enrolling by invitation | — | 40 | NuvOx LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04278118 | Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study(HiPPI) | recruiting | N/A | 70 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | active not recruiting | Phase 1 | 63 | Patrick Wen, MDOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04765514 | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | recruiting | Phase 2 | 107 | AHS Cancer Control AlbertaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06222138 | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma(EXOFIELDS) | recruiting | N/A | 80 | Institut Claudius RegaudOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07218367 | Phase I Trial of pH Resections of GBM at VA | not yet recruiting | Phase 1 | 12 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT03405792 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)(2-THE-TOP) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05139277 | Evaluation of the CONVIVO System | recruiting | N/A | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01535911 | Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors(Ketones) | active not recruiting | N/A | 16 | Michigan State UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | active not recruiting | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | recruiting | — | 120 | Baptist Health South FloridaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | not yet recruiting | Phase 1 | 8 | Jennifer LeddonOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06470711 | Mapping of Electrical Properties in the Brain | recruiting | — | 120 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT00639301 | Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life | active not recruiting | — | 473 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2026source: clinicaltrials